---
title: "Stoke Therapeutics, Inc. (STOK.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/STOK.US/overview.md"
symbol: "STOK.US"
name: "Stoke Therapeutics, Inc."
parent: "https://longbridge.com/en/quote/STOK.US.md"
datetime: "2026-04-04T19:53:47.942Z"
locales:
  - [en](https://longbridge.com/en/quote/STOK.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/STOK.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/STOK.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/STOK.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/STOK.US/overview.md)


# Stoke Therapeutics, Inc. (STOK.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 45 Wiggins Avenue, Bedford, Massachusetts, United States |
| Website | [www.stoketherapeutics.com](https://www.stoketherapeutics.com) |

## Company Profile

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials.

## Key Executives

| Name | Title |
|------|-------|
| Ian F. Smith | CEO & Director |
| Arthur O. Tzianabos | Chairman of the Board |
| Adrian R. Krainer | Co-Founder & Independent Director |
| Thomas Edward Leggett | Chief Financial Officer |
| Edward M. Kaye | Advisor & Director |
| Barry S. Ticho | Chief Medical Officer |
| Arthur A. Levin | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| FMR LLC | 9.47% | 2025-12-31 |
| RTW Investments, LP | 9.38% | 2025-12-31 |
| Lynx1 Capital Management LP | 9.14% | 2025-12-31 |
| BlackRock, Inc. | 8.81% | 2025-12-31 |
| Redmile Group, LLC | 6.82% | 2025-12-31 |
| Morgan Stanley | 5.95% | 2025-12-31 |
| Baker Bros. Advisors LP | 5.64% | 2025-12-31 |
| The Toronto-Dominion Bank | 5.36% | 2025-12-31 |
| Cowen Inc. | 5.36% | 2025-09-30 |
| The Vanguard Group, Inc. | 5.32% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Pharmaceuticals | 184420000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Stoke Therapeutics, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Pharmaceuticals",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| North America | 184420000 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**